Particle.news
Download on the App Store
3 ARTICLES
·
2w ago

Brexit Red Tape Blocks NHS Cancer Patients from Life-Saving Drugs, Report Finds

A new report reveals how post-Brexit regulatory hurdles and soaring costs are stalling clinical trials, leaving UK patients without access to critical treatments.

Image
Image

Overview

  • A comprehensive April 2025 report highlights how Brexit-induced red tape and costs have disrupted cancer research and denied NHS patients access to life-saving drugs.
  • The cost of importing cancer trial drugs to the UK has nearly quadrupled, with shipping expenses rising up to tenfold since Brexit, delaying trial launches and treatments.
  • Regulatory changes requiring duplicate certifications for trial drugs in the UK have caused significant delays, with some trials opening in the EU while UK patients wait.
  • UK researchers face challenges attracting global talent and securing EU grant funding, further weakening the nation’s cancer research ecosystem.
  • Charities and researchers are stepping in to fill funding gaps as political and scientific leaders push for a UK-EU mutual recognition agreement to streamline trials and reduce costs.